• β-Amanitin in Transcriptional Studies: Workflows & Innovatio

  2026-05-14

  Harness β-Amanitin's unique inhibition of RNA polymerase II to dissect gene expression mechanisms and improve mRNA synthesis inhibition assays. This guide distills protocol enhancements, troubleshooting insights, and the translational value of computationally guided detection methods, all grounded in cutting-edge research and APExBIO’s high-purity offering.

• DMH-1 (SKU B3686): Precision ALK2 Inhibition for Organoid an

  2026-05-13

  This scenario-driven article guides biomedical researchers and lab technicians through the practical deployment of DMH-1 (SKU B3686), a selective ALK2 inhibitor, to address reproducibility obstacles in cell viability, proliferation, and cytotoxicity assays. Drawing on recent peer-reviewed advances and validated workflows, it demonstrates how DMH-1 delivers reliable BMP signaling inhibition for organoid and non-small cell lung cancer (NSCLC) models, with actionable guidance on protocol optimization and vendor selection.

• MHY1485: Precision mTOR Activation for Next-Gen Autophagy As

  2026-05-13

  Explore how MHY1485, a potent mTOR activator, enables unprecedented control in autophagy assays and ovarian follicle development research. This article reveals new, actionable insights grounded in recent mechanistic studies and offers protocol guidance distinct from prior reviews.

• Targeting the ERα DBD-LBD Interface with Mitoxantrone: A Nov

  2026-05-12

  This study uncovers a previously unexploited vulnerability in estrogen receptor alpha (ERα), demonstrating that mitoxantrone binds the DBD-LBD interface to drive rapid receptor degradation via proteasomal pathways. The work establishes a new paradigm for DNA topoisomerase II inhibitors in overcoming resistance in breast cancer, with significant implications for research on receptor dynamics and therapeutic intervention.

• D-Luciferin Sodium Salt: Optimizing Bioluminescence in Oncol

  2026-05-12

  D-Luciferin sodium salt is the gold-standard firefly luciferase substrate, enabling ultra-sensitive, ATP-dependent bioluminescence assays for cell viability and metabolism monitoring. Discover how cutting-edge workflows, including mRNA-LNP programming of CAR macrophages, are revolutionizing bioluminescence imaging in oncology research with this robust reagent.

• Adefovir (GS-0393): Optimizing HBV Antiviral Research Workfl

  2026-05-11

  Adefovir (GS-0393) stands apart as a water-soluble, high-purity nucleotide analog for hepatitis B virus (HBV) research, offering robust DNA polymerase inhibition and precise OAT1 transporter probing. This guide details practical protocols, advanced use-cases, and troubleshooting strategies to maximize the translational reliability of your antiviral studies.

• CX-5461: RNA Polymerase I Inhibitor for Advanced Cancer Rese

  2026-05-11

  CX-5461 from APExBIO stands out as a robust, orally bioavailable RNA polymerase I inhibitor, enabling precise targeting of ribosome biogenesis in cancer cells. With deep literature support and protocol-driven reliability, it empowers researchers to interrogate autophagy, senescence, and chemoresistance mechanisms in solid tumors with unprecedented clarity.

• Fluconazole: Mechanistic Benchmark for Antifungal Resistance

  2026-05-10

  Fluconazole remains the gold standard fungal cytochrome P450 enzyme 14α-demethylase inhibitor for dissecting antifungal resistance mechanisms in vitro and in vivo. This article details advanced experimental workflows, troubleshooting insights, and evidence-driven protocol refinements that maximize the reliability and translational value of Fluconazole in fungal pathogenesis research.

• Amorolfine Hydrochloride: Applied Antifungal Workflows & Ins

  2026-05-09

  Amorolfine Hydrochloride unlocks advanced antifungal research by enabling precise membrane disruption assays and novel ploidy stress investigations. This guide translates bench protocols and reference breakthroughs into actionable, data-backed workflows for scientists dissecting fungal cell integrity and antifungal resistance.

• Mitochondrial ROS-Linked Apoptosis and Muscle Atrophy in Ova

  2026-05-09

  This study investigates the role of mitochondrial reactive oxygen species (ROS) in driving apoptosis and necroptosis during muscle atrophy in metastatic ovarian cancer. By targeting mitochondrial ROS with SkQ1, the authors reveal that suppressing apoptotic caspase activity does not prevent muscle atrophy, challenging prevailing assumptions about cell death pathways in cancer cachexia.

• MMP7 Drives EMT and Liver Fibrosis via E-cadherin/β-Catenin

  2026-05-08

  This study uncovers how matrix metalloproteinase 7 (MMP7) promotes liver fibrosis in biliary atresia (BA) by inducing epithelial–mesenchymal transition (EMT) through the E-cadherin/β-catenin signaling pathway. The findings offer mechanistic insights and highlight the therapeutic potential of directly targeting MMP7 or downstream β-catenin activity in fibrotic liver disease.

• Amphotericin B: Applied Protocols for Fungal Infection Resea

  2026-05-07

  Leverage Amphotericin B’s potent antifungal activity for robust cell-based and mechanistic assays. This guide details experimental workflows, troubleshooting strategies, and protocol enhancements, enabling reproducible and insightful outcomes in fungal infection research.

• Azithromycin: Mechanistic Advances and Translational Impact

  2026-05-07

  This article delivers a strategic, evidence-based perspective on the use of Azithromycin—a potent macrolide antibiotic—in bacterial infection research and trypanosomosis models. We bridge mechanistic insight with actionable experimental guidance, contextualize APExBIO’s offering within the competitive landscape, and provide protocol benchmarks, translational context, and a forward-looking outlook for translational researchers.

• Tomentodione M Reverses Docetaxel Resistance via P-gp/p38 MA

  2026-05-06

  This study demonstrates that tomentodione M, a natural meroterpenoid, sensitizes multidrug-resistant cancer cells to chemotherapeutic agents such as Docetaxel by downregulating P-glycoprotein through inhibition of p38 MAPK signaling. The findings offer a mechanistic rationale for targeting the P-gp/p38 MAPK axis to overcome clinical drug resistance, providing a foundation for future cancer chemotherapy research.

• Practical Guide to Oligo (dT) 25 Beads for mRNA Purification

  2026-05-06

  Oligo (dT) 25 Beads enable efficient and selective eukaryotic mRNA isolation by targeting polyA tails, supporting downstream applications such as RT-PCR and sequencing. This product is best suited for workflows requiring high-purity mRNA from total RNA or cell lysates, but is not recommended for non-polyadenylated RNA species or prokaryotic samples.

16361 records 1/1091 page Next 12345 下5页 Last page